HSBC set a €160.00 ($186.05) price objective on Sartorius (FRA:SRT3) in a research report released on Wednesday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

Other equities research analysts have also issued reports about the company. Nord/LB set a €125.00 ($145.35) price target on Sartorius and gave the stock a sell rating in a research note on Monday, July 22nd. Deutsche Bank set a €170.00 ($197.67) price target on Sartorius and gave the stock a neutral rating in a research note on Tuesday, October 15th. Berenberg Bank set a €145.00 ($168.60) price target on Sartorius and gave the stock a sell rating in a research note on Thursday, July 25th. UBS Group set a €184.00 ($213.95) price target on Sartorius and gave the stock a neutral rating in a research note on Friday, July 19th. Finally, Hauck & Aufhaeuser set a €135.00 ($156.98) price target on Sartorius and gave the stock a sell rating in a research note on Friday, August 23rd. Five equities research analysts have rated the stock with a sell rating and four have issued a hold rating to the stock. The stock has a consensus rating of Sell and an average target price of €147.61 ($171.64).

Shares of SRT3 stock opened at €167.90 ($195.23) on Wednesday. Sartorius has a 52-week low of €71.00 ($82.56) and a 52-week high of €124.70 ($145.00). The stock has a 50 day moving average price of €171.00 and a 200 day moving average price of €172.49.

Sartorius Company Profile

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.

Recommended Story: How Do I Invest in Dividend Stocks

Analyst Recommendations for Sartorius (FRA:SRT3)

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.